HealthTech Growth · 2024-04-02 · 9 min
Key moments - from our scoring
Substance score
36 / 100
Five dimensions, 20 points each
Triox Nano, founded in 2015 by Dr. Rui Farfara, uses DNA molecular machines to create programmable diagnostic and therapeutic technologies that could transform how medicines are manufactured and distributed. Rather than following traditional pharmaceutical development paths, Triox Nano partners with large pharma and technology companies to license their five proprietary technologies (two diagnostic, three therapeutic) based on DNA sequences. The core innovation involves programming mesoporous particles with DNA machines that can be triggered to release their payload at predetermined times - essentially converting drug manufacturing from a logistics-heavy physical process into a programmable information system. Farfara explains that medicines could theoretically be printed anywhere using DNA printers, from spacecraft to naval vessels, eliminating the need for traditional manufacturing and supply chains. Board advisor Shawna Dixon Smith frames the core challenge: selling an intangible ecosystem and idea rather than a physical product requires translating disruptive concepts into relatable metaphors, simple language avoiding jargon, and anchoring pitches to familiar industry statistics and metrics that investors can understand and evaluate.
Triox Nano uses DNA molecular machines to create programmable technologies that cap mesoporous particles and release their payload at predetermined times; they have developed five technologies total (two diagnostic, three therapeutic) all based on DNA sequences.
Instead of manufacturing, storing, and logistically transporting physical drugs, medicine could be printed locally using DNA printers from programmable sequences, enabling production anywhere from spacecraft to naval vessels without traditional supply chain infrastructure.
Triox Nano is a preclinical biotech company with no revenues that licenses its patents, proof-of-concepts, and ideas to large pharma and technology companies to conduct clinical studies and product development rather than pursuing drug development itself.
Keep explanations very simple using short words and no jargon, relate the offering to something investors are already familiar with through metaphors, and provide numbers, statistics, or metrics - either from your innovation or from the industry you're disrupting.
Our reviewer’s read on each dimension, with quotes from the episode.
The episode contains some interesting foundational concepts (DNA as programmable machines, the vision of medicine printing) but heavily weighted toward generic advice about investor communication and persuasion that applies to any founder pitching intangibles. Most of the substantive technical detail comes in the first 3 minutes; the remainder is recycled frameworks about simplicity, relatability, and metrics that any B2B operator has heard before.
DNA and RNA started in the beginning of life as machines
We could cap these particles in advance knowing when they will uncap
While the DNA-based programmable therapeutics concept itself is novel, the episode's substantive contributions devolve quickly into tired tropes about 'changing mindsets,' 'disruption,' and the flat-Earth analogy, which are ubiquitous in startup discourse. The investor-pitching framework (simplicity, relatability, metrics) is entirely conventional.
Think back to when the earth was flat instead of round
Changing global mindsets has been done before
Dr. Rui Farfara is a legitimate founder-operator with surgical and research background who started Triox Nano in 2015 and holds patents in DNA-based therapeutics. However, the episode is short (9 min) and he only speaks briefly before being displaced by Shawna Dixon Smith, a career advisor with no direct operating experience in biotech or healthcare scaling, reducing overall caliber.
My name is Dr. Rui Farfara. I am the CEO and the founder of Triox Nano
I am a surgeon and I'm a researcher
The episode provides some specific technical details (Triox Nano founded 2015, five programmable technologies, two diagnostic and three therapeutic, DNA mesoporous particle capping) but lacks concrete evidence of efficacy, clinical stage, timelines, or commercial metrics. The investor communication section uses only abstract examples (the onion metaphor) rather than named case studies or financial data.
Triox Nano is a company uh, that I started in 2015
We have five different programmable technologies. Uh two of them are diagnostic and three of them are therapeutic
The host (Speaker C) does not ask Roy substantive follow-up questions about technology readiness, regulatory pathway, partnerships sought, or commercial timeline. Instead, the host launches into a long monologue on investor communication that derails the conversation and treats Roy's remarks as a springboard for generic advice rather than digging deeper into his specific challenges and insights.
I want to take this opportunity to speak to
Let me share some key frameworks for how you should pitch
Computed from the transcript - who did the talking, and the words that came up most.
Ever wondered how the frontiers of cancer treatment are being redefined through DNA technology? This episode with Roy from Triox Nano dives into the intersection of groundbreaking healthcare innovation and strategic business growth, illuminating the path from concept to market-ready cancer treatment solutions. What you will learn: 1. The journey of Triox Nano from a visionary idea to a leading force in cancer treatment innovation. 2. Strategies for conveying the value of complex innovations to investors and the marketplace. 3. The importance of metaphors and relatable experiences in simplifying and selling intangible concepts. 4. How to effectively communicate with investors using simplicity, familiarity, and hard data. Feel inspired by Roy's journey and have insights to share? Apply to be a speaker and
Transcribed and scored by The B2B Podcast Index.
Speaker A: Ever wondered who's pioneering the advancements in cancer treatment through cutting edge DNA technology? Listen in as Roy details his experience with Triox Nano, highlighting his unicorn startup's journey in leveraging DNA advancements to transform cancer care while navigating the challenges and opportunities of bringing such a, ah, pioneering strategy to the forefront.
Speaker B: Welcome to Health Tech Growth, the weekly podcast for health care founders and innovators where we explore essential strategies to create successful and sustainable healthcare startups that improve patient outcomes, um, and transform the healthcare industry.
Speaker C: As a board advisor for Pulse Point Path, I, Shawna Dixon Smith lend 17 years of expertise in purpose alignment with a passion for scaling businesses to their full potential. Specializing in synchronizing an individual's highest purpose with their company's vision, I craft strategies that not only accelerate personal growth, but also advance business objectives. My methodology ensures teams are uh, aligned, motivated and fully engaged with their work, driving companies toward unparalleled success. Now let's listen as Roy shares his pioneering journey, offering a glimpse into the innovative mindset and shaping the future of healthcare.
Speaker D: My name is Dr. Rui Farfara. I am the CEO and the founder of Triox Nano. Uh, Triox Nano is a company uh, that I started in 2015 understanding that uh, you know, all the world around us is digital. Uh, we have smart homes, we have smart cars, but we don't have smart drugs. Medications uh, are analog and um, in my background I am a surgeon and I'm a researcher. I worked in the technion, um, and I um, got acquainted with digital technologies in the biological world using DNA molecular machines. So actually everyone is familiar with DNA being a storage, um, access or a storage uh, facility. But DNA and RNA started in the beginning of life as machines. And there are different machines including in our cells that are made of DNA. And um, in the last 20 years the scientific uh, community has taken this machine forwards and created uh, some pretty amazing technologies that are actually made of DNA sequences, uh, using these DNA machines to cap mesoporous particles, particles that have many pores. But we could cap these particles in advance knowing when they will uncap. So this was the first phase of programming. It was pre programmed to open when we wanted it to open. Fast forward to today. Um, we actually have five different programmable technologies. Uh two of them are diagnostic and three of them are therapeutic, uh, that are all based on DNA machines. So first to be uh, transparent. We have no revenues. We are a uh, biotech preclinical company. Okay. We invent the technologies, we invent the basic science. We are Less interested in following up, uh, with products in other4 technologies. We are actually looking to cooperate with the large pharma to cooperate, uh, with technology companies that would like to take this, uh, patents, to take these ideas, to take these proof of concepts and to follow up with clinical studies. And that's actually our challenge because on one hand we are totally disrupting a giant industry. On the other hand, um, if you know it's hard to change the mindset, it's hard to understand that you can print medicine in a DNA printer because all these DNAs are actually printable. So now you are actually talking about not a pharmaceutical company that is manufacturing and is storaging and logistically transferring. You are turning everything into programming. So I can share with you any sequence that I programmed and I proved that works and you can print it locally wherever you are, it doesn't matter. Elon Musk on the way to Mars or a navy ship on the way to Israel, uh, they can use the information to make the medicine or the diagnostic test, uh, and that's uh, disruptive and hard to persuade. Uh, and that's our issue.
Speaker C: I want to take this opportunity to speak to. When you are totally disrupting a giant industry and it's hard to change the mindset. And this does also correlate to when it's hard to explain your value to investors or customers. Especially when you are selling a concept or ecosystem or idea, basically an intangible versus a physical product. When you find yourself in this position, start by seeking inspiration. Changing global mindsets has been done before. Think back to when the earth was flat instead of round. Or the hypothesis that illness was caused by tiny invisible creatures jumping from person to person before the microscope existed to reveal germs, it's helpful to look back and see the pattern of how those ideas were finally accepted. How can you bridge your work with a metaphor or experience your audience has already had? You can hear how it became easier for Roy. Once there was a similar concept in the marketplace to compare to. In my work I've had similar issues as what I do doesn't exist in the marketplace today, I use the metaphor of how what I do is like an onion and what we are doing is cutting out the core so all the layers fall away. Instead of having to peel back one layer of problems at a time. This is relatable because most people have experienced an onion and its layers. So what can you find that's relatable for your innovative offering? That leads me to the key elements you need when seeking and speaking to investors. Investors prefer tangible, measurable goods for obvious reasons. It speaks to the security of their investment and this is human nature. We can feel secure when we see it, touch it, and know what to expect, whereas with the intangible there is more room for confusion and confused. People don't invest. So when seeking investment, there are three key elements. First, you must keep the explanation very simple. Do not use jargon. Use short words with as few syllables as possible, and pause after key short phrases. Second, it must relate to something they are very familiar and comfortable with, like the example we just talked about with the Onion. And third, you need numbers, statistics and metrics of some kind. If your offering is so innovative it doesn't have a lot of statistics of its own, that's okay. You can utilize the statistics of the industry you are trying to change to emphasize the need or for investing in new solutions. Hopefully this has given you some ideas for how to be better understood as an innovator disrupting the marketplace. And now you can move forward with more confidence in your message as you go out there and change the world.
Speaker E: Thank you for listening to Health Tech Growth. If you are a health care tech innovator or founder interested in being a featured guest on our show, visit HealthTechGrowth IO to learn more.
Why Your Excellent Product Dies in the Final Stage37 / 100
Are You the Bottleneck in Your Own Company?29 / 100
How to Stop Being the Bottleneck in Your Own HealthTech Company26 / 100
Driving Growth in HealthTech: Miracle Mobility's Strategy for Success53 / 100
Transforming Fertility Experiences: The Role of Technology and Empathy57 / 100